Here's why the Antisense (ASX:ANP) share price is climbing 5% today

Investors are excited following the company's annual general meeting…

| More on:
A sophisticated older lady with shoulder-length grey hair and glasses sits on her couch laughing while looking at her phone

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Antisense Therapeutics Limited (ASX: ANP) share price is moving higher today. This upwards movement comes amid the company's annual general meeting (AGM). Usually, these events are not considered to be price-sensitive. However, the biotech's AGM was tagged as a price-sensitive market announcement today.

In afternoon trade, shares in the biotechnology company are up 5.56% to 19 cents. Despite the gain, shareholders are still nearly 46% away from the 52-week high set in October.

Let's take a closer look at what could be driving the Antisense share price higher today.

What has Antisense been up to?

Investors are bidding up the Antisense share price today as they are reminded of what the company has been doing in recent times.

As per the AGM presentation, the company's key focus remains developing ATL1102. Antisense informed shareholders of its United States regulatory plans today. As already known, the company has submitted its protocol synopsis to the US Food and Drug Administration (FDA) for a 9-month chronic monkey toxicology study.

Furthermore, the company highlighted it could be in a position to receive a rare pediatric disease priority review voucher (PRV). In order to land the PRV, Antisense will need to get FDA approval for ATL1102 in use for people with Duchenne Muscular Dystrophy before 30 September 2026.

Notably, in the past (2017 to 2021) PRVs have sold for between US$80 million to US$150 million. Such a deal would be significant for the company considering its annual revenue has been sub-$1 million since 2017.

In addition, the Antisense share price might be finding strength today as the company emphasises its ambition to expand the clinical application of ATL1102 beyond DMD.

Lastly, Antisense shareholders may be pleased with the company's current financial position. Thanks to a recent $20 million placement, Antisense is funded into the second half of the 2023 calendar year. This includes costs associated with setting up the Phase IIb/III DMD trial in Europe.

Antisense share price recap

Despite losses widening to about $8 million in the past financial year, the Antisense share price has performed strongly in 2021.

Since January, the company's shares have gained 35.7% in value. For context, the S&P/ASX 200 Index (ASX: XJO) is up 9.7% over the same time span.

Motley Fool contributor Mitchell Lawler has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

CSL shares are in the red for 2024. Are they a buy?

Meanwhile, the broader market has extended to new highs this year.

Read more »

A smiling businessman in the city looks at his phone and punches the air in celebration of good news.
Share Market News

Guess which ASX 300 stock is jumping 11% on big news

Big news is giving this stock an even bigger lift on Tuesday. What's happening?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 200 healthcare stock is starting the week with a bang on big news!

What is getting investors excited today? Let's find out.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

3 small-cap ASX healthcare shares 'with strong prospects'

Fund manager IML discusses why these 3 ASX healthcare shares are likely to rise in value.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

These two ASX healthcare companies are seeing heavy trading on Thursday.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

'Trading at a discount': Why now is the time to buy CSL shares

This investing expert says CSL shares now represent an appealing buying opportunity.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Here's what could impact CSL shares from the biotech's AGM

The biotech giant's leadership had plenty to say.

Read more »

Man with a sleep apnoea mask on whilst sleeping.
Healthcare Shares

Why this fundie is backing ResMed shares in FY25

There's plenty more upside, this fund says.

Read more »